Skin Elements Allots 337,272,727 Shares Under Section 708A Notice

Mukul

09 November 2026 07:00 PM AEDT

Skin Elements Allots 337,272,727 Shares Under Section 708A Notice

Image Source: Krish Capital Pty Ltd

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Skin Elements Limited (ASX:SKN), an Australian biotechnology company, has completed an allotment of 337,272,727 fully paid ordinary shares and lodged a notice under section 708A(5)(e) of the Corporations Act 2001, the company disclosed on 9 November 2026.

Key Points

337,272,727 fully paid ordinary shares have been allotted in the capital of the company
The shares were issued without disclosure under Part 6D.2 of the Corporations Act 2001
An Appendix 2A has been lodged with the allotment
The company states there is no "excluded information" as defined under section 708A(7) required to be disclosed under section 708A(8) of the Corporations Act

Section 708A Notice Details

According to the filing, Skin Elements has given notice pursuant to section 708A(5)(e) of the Corporations Act 2001 that the shares were issued without disclosure under Part 6D.2 of the Act. The company further stated that, as at the date of the notice, it has complied with the provisions of Chapter 2M of the Corporations Act as they apply to the company, as well as with section 674 and section 674A of the Corporations Act. The filing was authorised for release by the Board.

Excluded Information Disclosure

The company disclosed that, as at the date of the notice, there is no information that constitutes "excluded information" as defined in section 708A(7) of the Corporations Act that is required to be disclosed by the company in accordance with section 708A(8) of the Corporations Act. The company also confirmed that an Appendix 2A has been lodged in connection with the completed allotment of fully paid ordinary shares.

Company Overview

Skin Elements is described in the filing as an Australian-owned and operated ASX-listed biotechnology healthcare company focused on the commercialisation of the anti-microbial SE Formula through a range of natural and organic healthcare products. Its product portfolio, according to the filing, includes the SuprCuvr TGA-registered hospital-grade plant-based disinfectant, Eco Nurture plant bio-stimulant, Invisi Shield alcohol-free natural sanitiser, TGA-registered Soléo Organics sunscreen, TGA-registered PapayaActivs natural therapeutics skincare, and Elizabeth Jane Natural Cosmetics brand.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.